Beranda › Kanker Paru › Connecticut › Stamford
Uji klinis Kanker Paru di Stamford, CT
10 studi untuk Kanker Paru mencari peserta di lokasi sekitar Stamford (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Menerima pesertaFase 3
- Stamford Hospital/Bennett Cancer Center, Stamford
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi jauhnya
- Good Samaritan University Hospital, West Islip · 27 mi jauhnya
- Northwell Health Imbert Cancer Center, Bay Shore · 27 mi jauhnya
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Menerima pesertaFase 3
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Stamford Hospital/Bennett Cancer Center, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi jauhnya
- dan 1 lainnya
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Menerima pesertaFase 3
- Stamford Hospital ( Site 0083), Stamford
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Northwell Health Cancer Institute at Huntington, Greenlawn · 16 mi jauhnya
- Northwell Health Imbert Cancer Center, Bay Shore · 27 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi jauhnya
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Menerima pesertaStudi observasional
- Stamford Hospital, Stamford
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Menerima pesertaStudi observasional
- The Stamford Health/The Stamford Hospital, Stamford
- Good Samaritan Cancer Center, West Islip · 27 mi jauhnya
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Stamford
- Kanker Payudara9 studi
- Kanker Paru Non-Sel Kecil8 studi
- Migrain6 studi
- Obesitas6 studi
- Kanker Prostat5 studi
- Kanker Ovarium5 studi
- Kanker Pankreas4 studi
- Penyakit Kardiovaskular4 studi
- Kelebihan Berat Badan4 studi
- Kanker Metastatik3 studi
- Penyakit Neurologis3 studi
- Gagal Jantung3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.